A medical device manufacturer has announced its second large expansion in Columbus in less than a year.

BD said Tuesday that it will invest $110 million to expand its production of prefillable syringes in Columbus. The expansion will add approximately 120 more jobs in the city where BD already employs more than 2,000 workers at two manufacturing plants.

Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems, said the Columbus expansion is in large part being driven by the popularity of GLP-1s, which are injectable weight-loss medications.

“This investment in Nebraska, advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions,” Jeukenne said in a news release.

Tuesday’s announcement comes on the heels of an announcement in August that the company would invest $35 million to upgrade and expand its pre-filled flush syringe manufacturing at one of its plants in Columbus, a move that will add 50 jobs.

Sen. Pete Ricketts called Tuesday’s announcement “good news for Nebraska.”

“This investment further underscores BD’s ongoing commitment to keep critical manufacturing in states like Nebraska,” Ricketts said in a statement. “I appreciate BD’s longstanding partnership with the Cornhusker State.”

BD’s growth in Columbus has been one of the few bright spots in the state’s manufacturing sector, which has declined over the past year under the weight of tariffs.

According to the Nebraska Department of Labor, the sector lost almost 2,000 jobs from November 2024 to November 2025.

The amount of manufacturing exports from Nebraska also has declined sharply, falling from $5.3 billion in the first nine months of 2024 to $4.6 billion in the same period this year, according to Creighton University’s Mid-America Business Conditions Index.